Business
Enovis develops orthopedic devices and rehabilitation technology.
Enovis grew revenue, reported a net loss, generated positive free cash flow at a -50.0% operating margin. A very large reported loss and negative margin reflected major charges; positive free cash flow did not make those items recurring operations.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 6.7%OK
- Profitability — The net loss widened from $825.494M to $1.184BWatch
- Cash flow — Free cash flow turned positive at $19.917M from an outflow of $67.21MOK
- Margins — Operating margin contracted 1320 bps to -50.01%Watch
- Accounting — A very large reported loss and negative margin reflected major chargesWatch
- Insiders — 16 purchases and 1 salesOK
Where the revenue comes from
Fiscal 2025, as Enovis CORP reports it. History and quarterly detail are in the app.
- Prevention & Recovery:$1.1B
- Reconstructive:$1.1B
Leadership changes
From Enovis CORP's own filings, the day they're filed.
- Daniel A. Pryor · Directors · departureeff. 2025-11-07
- Damien McDonald · Chief Executive Officer · appointmenteff. 2025-05-12
- Matthew L. Trerotola · Chief Executive Officer · appointmenteff. 2025-02-25
Latest filings
- 8-K · Company announcement2026-09-01
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Enovis CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.